Abcam’s new premium-grade bioactive proteins, for drug discovery, development and manufacturing
Cambridge, UK, 3rd November 2020 – Abcam’s new premium-grade bioactive proteins are highly-active growth factors and cytokines manufactured and designed to meet the specific needs of cell culture, including cell and gene therapy and regenerative medicine.
Sourcing high-quality proteins with batch-to-batch consistency can be a challenge, as endotoxin levels and/or non-native protein conformations and post-translational modifications can affect safety and performance.
Abcam’s new premium-grade proteins are manufactured in mammalian cell lines under animal-free conditions limiting endotoxins to ultra-low levels (< 5 EU/mg). The use of mammalian cell lines produces proteins with the desired conformation and correct post-translational modifications for optimal bioactivity. They resemble the proteins’ native state, helping to ensure a safe and consistent outcome during drug discovery, development and manufacturing.
Developed by a team of industry-expert protein scientists, each batch is validated using state-of-the-art technology to ensure consistent quality regarding integrity, purity, concentration, mono-dispersity and correct folding.
Abcam can also design, manufacture and validate proteins to custom needs and specifications. As a supplier of proteins for a broad range of applications, Abcam provides a comprehensive range of bioactive and research-grade proteins that enable additional cost-effective quality solutions.
Abcam’s premium-grade bioactive proteins provide:
- Superb bioactivity
- Ultra-low endotoxin levels, < 5 EU/mg
- Native post-translational modifications
- > 95% purity
- Carrier-free, tag-free
- Manufactured under ISO9001
- Batch-to-batch consistency monitored by sophisticated quality control, addressing identity, integrity, purity, concentration, folding and aggregation using methods such as LCMS, light scattering and thermal denaturation
- Premium protein product certificate of analysis provided
To find out more, please visit www.abcam.com and www.abcamplc.com.
For more information please contact Abcam’s External Communications team at external.comms@abca